Literature DB >> 12432901

[Role of receptor tyrosine kinase in the angiogenesis].

S Meyer1, C Hafner, T Vogt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12432901     DOI： 10.1007/s00105-002-0425-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


× No keyword cloud information.
  26 in total

Review 1.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

Authors:  N W Gale; G D Yancopoulos
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 3.  The ephrins and Eph receptors in angiogenesis.

Authors:  Nikki Cheng; Dana M Brantley; Jin Chen
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

4.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Authors:  J M Wood; G Bold; E Buchdunger; R Cozens; S Ferrari; J Frei; F Hofmann; J Mestan; H Mett; T O'Reilly; E Persohn; J Rösel; C Schnell; D Stover; A Theuer; H Towbin; F Wenger; K Woods-Cook; A Menrad; G Siemeister; M Schirner; K H Thierauch; M R Schneider; J Drevs; G Martiny-Baron; F Totzke
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

5.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

6.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Authors:  A D Laird; P Vajkoczy; L K Shawver; A Thurnher; C Liang; M Mohammadi; J Schlessinger; A Ullrich; S R Hubbard; R A Blake; T A Fong; L M Strawn; L Sun; C Tang; R Hawtin; F Tang; N Shenoy; K P Hirth; G McMahon
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

7.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Authors:  R A Brekken; J P Overholser; V A Stastny; J Waltenberger; J D Minna; P E Thorpe
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

8.  Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.

Authors:  B A Teicher; E A Sotomayor; Z D Huang
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

9.  Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.

Authors:  M Saleh; S A Stacker; A F Wilks
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

Review 10.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440
View more
  1 in total

1.  Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.

Authors:  Birgit Mosch; Bettina Reissenweber; Christin Neuber; Jens Pietzsch
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.